Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation.

Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver N, Verstovsek S, Champlin RE, Popat UR.

Haematologica. 2019 Jul 11. pii: haematol.2019.223503. doi: 10.3324/haematol.2019.223503. [Epub ahead of print]

2.

Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning.

van Besien K, Artz A, Champlin RE, Guarneri D, Bishop MR, Chen J, Gergis U, Shore T, Liu H, Rondon G, Mayer SA, Srour SA, Stock W, Ciurea SO.

Blood Adv. 2019 Jun 25;3(12):1858-1867. doi: 10.1182/bloodadvances.2019000200.

3.

Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long term results of a prospective phase II clinical trial.

Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Molldrem JJ, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR.

Haematologica. 2019 Apr 4. pii: haematol.2018.214429. doi: 10.3324/haematol.2018.214429. [Epub ahead of print]

4.

Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens.

Maymani H, Lin P, Saliba RM, Popat U, Bashir Q, Shah N, Patel K, Parmar S, Kebriaei P, Hosing C, Ciurea S, Andersson B, Shpall E, Champlin R, Srour SA, Qazilbash MH.

Biol Blood Marrow Transplant. 2019 May;25(5):1039-1044. doi: 10.1016/j.bbmt.2019.01.009. Epub 2019 Jan 11.

PMID:
30639822
5.

Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial.

Popat UR, Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Jones R, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Rezvani K, Qazilbash MH, Shah N, Srour SA, Shpall EJ, Champlin RE, Andersson BS.

Lancet Haematol. 2018 Nov;5(11):e532-e542. doi: 10.1016/S2352-3026(18)30156-X.

PMID:
30389035
6.

Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).

Jain P, Romaguera J, Srour SA, Lee HJ, Hagemeister F, Westin J, Fayad L, Samaniego F, Badillo M, Zhang L, Nastoupil L, Kanagal-Shamanna R, Fowler N, Wang ML.

Br J Haematol. 2018 Aug;182(3):404-411. doi: 10.1111/bjh.15411. Epub 2018 May 22.

PMID:
29785709
7.

Paraneoplastic Hyperleukocytosis in Pancreatic Adenocarcinoma.

Wu ES, Srour SA.

J Pancreat Cancer. 2017 Nov 1;3(1):84-86. doi: 10.1089/pancan.2017.0019. eCollection 2017.

8.

Impact of Health Care Insurance Status on Treatment Outcomes of Acute Myeloid Leukemia.

Srour SA, Machiorlatti M, Pierson NT, Bhutta UZ, Cherry M, Selby GB, Thompson DM, Vesely SK, Kurkjian CD.

Clin Lymphoma Myeloma Leuk. 2017 Jul;17(7):450-456.e2. doi: 10.1016/j.clml.2017.05.011. Epub 2017 May 10.

PMID:
28624543
9.

A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.

Srour SA, Li S, Popat UR, Qazilbash MH, Lozano-Cerrada S, Maadani F, Alousi A, Kebriaei P, Anderlini P, Nieto Y, Jones R, Shpall E, Champlin RE, Hosing C.

Br J Haematol. 2017 Aug;178(4):561-570. doi: 10.1111/bjh.14731. Epub 2017 May 9.

10.

Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma.

Srour SA, Lee HJ, Nomie K, Ye H, Chen W, Oriabure O, Romaguera J, Wang ML.

Br J Haematol. 2018 May;181(4):561-564. doi: 10.1111/bjh.14669. Epub 2017 Apr 2. No abstract available.

PMID:
28369820
11.

Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia.

Srour SA, Milton DR, Bashey A, Karduss-Urueta A, Al Malki MM, Romee R, Solomon S, Nademanee A, Brown S, Slade M, Perez R, Rondon G, Forman SJ, Champlin RE, Kebriaei P, Ciurea SO.

Biol Blood Marrow Transplant. 2017 Feb;23(2):318-324. doi: 10.1016/j.bbmt.2016.11.008. Epub 2016 Nov 14.

12.

Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation.

Bock F, Lu G, Srour SA, Gaballa S, Lin HY, Baladandayuthapani V, Honhar M, Stich M, Shah ND, Bashir Q, Patel K, Popat U, Hosing C, Korbling M, Delgado R, Rondon G, Shah JJ, Thomas SK, Manasanch EE, Isermann B, Orlowski RZ, Champlin RE, Qazilbash MH.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2159-2164. doi: 10.1016/j.bbmt.2016.09.003. Epub 2016 Sep 13.

13.

Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.

Srour SA, Devesa SS, Morton LM, Check DP, Curtis RE, Linet MS, Dores GM.

Br J Haematol. 2016 Aug;174(3):382-96. doi: 10.1111/bjh.14061. Epub 2016 Apr 7. Erratum in: Br J Haematol. 2017 Apr;177(2):331.

14.

Role of topotecan, vinorelbine, thiotepa and gemcitabine chemotherapy in relapsed/refractory adult acute leukemia.

Srour SA, Borders EB, Cherry MA, Holter J, Herman T, Selby GB.

Leuk Lymphoma. 2015;56(10):2962-4. doi: 10.3109/10428194.2015.1018250. Epub 2015 Mar 31. No abstract available.

PMID:
25721752
15.

An unusual presentation of an aggressive spindle cell skin cancer.

Srour SA, Workman M, Yang JT, Abdullah SA, Cherry MA.

J Community Support Oncol. 2014 Apr;12(4):149-52.

PMID:
24971424
16.

Incidence of potentially human papillomavirus-related neoplasms in the United States, 1978 to 2007.

Kurdgelashvili G, Dores GM, Srour SA, Chaturvedi AK, Huycke MM, Devesa SS.

Cancer. 2013 Jun 15;119(12):2291-9. doi: 10.1002/cncr.27989. Epub 2013 Apr 11.

Supplemental Content

Loading ...
Support Center